Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
1
14%
Ph phase_3
5
71%

Phase Distribution

0

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
5(83.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (16.7%)
Phase 35 (83.3%)

Trials by Status

completed571%
terminated114%
unknown114%

Recent Activity

0 active trials
Showing 5 of 7
unknown

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

NCT02189720
terminatedphase_3

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

NCT03579966
completedphase_3

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

NCT03304054
completedphase_2

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

NCT03781479
completedphase_3

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

NCT02562066
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT02189720

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

Unknown
NCT03579966Phase 3

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Terminated
NCT03304054Phase 3

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Completed
NCT03781479Phase 2

Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients

Completed
NCT02562066Phase 3

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Completed
NCT02970162Phase 3

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Completed
NCT01377922Phase 3

A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7